---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-125113"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:47:06.626818+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Federal Circuit schedules May 11, 2026 oral argument for Enanta's patent appeal against Pfizer over Paxlovid

## Summary
- Federal Circuit oral argument in Enanta's patent appeal against Pfizer (Paxlovid) set for May 11, 2026.
- Enanta originally filed suit for infringement of U.S. Patent No. 11,358,953 related to Paxlovid.
- Notice of appeal was filed on February 3, 2025.
- The appeal is before the U.S. Court of Appeals for the Federal Circuit.

## SEC filing metadata
- accession: 0001193125-26-125113
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000119312526125113/0001193125-26-125113-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000119312526125113/enta-20260320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-125113
- JSON: https://secwatch.observer/filing/0001193125-26-125113.json
- Plain text: https://secwatch.observer/filing/0001193125-26-125113.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.